Hepcidin: Physiology and What Research Reports

What is hepcidin?

Hepcidin is a small, cysteine-rich peptide hormone that acts as the body's principal regulator of systemic iron availability. Review literature has described it as the master hormone controlling dietary iron absorption, iron recycling from macrophages and iron release from storage, with its concentration rising and falling to match the body's iron demand (Hepcidin and Iron in Health and Disease). Because it is a peptide with a defined receptor-like target, hepcidin appears frequently in peptide literature alongside better-known hormones, and the term is often encountered in discussions of iron panels, anaemia and inflammation.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, laboratory result or treatment decision. Nothing here describes a protocol, and no dose is presented except where a cited paper's published scope included it.

Where hepcidin is produced and what it does

Hepcidin is synthesised predominantly by hepatocytes in the liver, with smaller contributions described from other tissues, and it circulates to reach cells that export iron. Reviews of hepcidin biology reported that hepatic hepcidin production responds to iron stores, erythropoietic demand, inflammation and hypoxia, making the liver a sensing hub for whole-body iron balance (Regulators of hepcidin expression).

The ferroportin mechanism

The mechanistic basis for hepcidin's action was established in work reporting that hepcidin regulates cellular iron efflux by binding to the iron exporter ferroportin and inducing its internalisation, removing the transporter from the cell surface (Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization). Because ferroportin is the route by which duodenal enterocytes, macrophages and hepatocytes release iron into plasma, later reviews described high hepcidin as restricting iron entry to the circulation and low hepcidin as permitting it (Hepcidin and Iron in Health and Disease). This single axis is why hepcidin is discussed in both iron-overload states and iron-restricted anaemias.

How hepcidin is measured and studied

Hepcidin is typically studied by measuring the circulating peptide in serum or plasma, by quantifying hepatic HAMP gene expression in animal and cell models, and by manipulating its upstream regulators. Review work summarised the signalling inputs used experimentally — including bone morphogenetic protein signalling, erythroid factors and inflammatory cytokines — as the levers researchers use to raise or lower hepcidin expression in models (Regulators of hepcidin expression). Comparative studies add another approach: an analysis of hepcidin cDNA evolution across vertebrates was used to trace how the peptide's sequence and gene copies diverged between species (Hepcidin cDNA evolution in vertebrates).

What the literature reports across research areas

Iron overload and anaemia

In beta-thalassemia, a review of the field discussed how hepcidin behaves in the setting of ineffective erythropoiesis and how that relationship contributes to iron loading in this disorder (Hepcidin in beta-thalassemia). Broader review literature reported that disordered hepcidin signalling underlies both hereditary iron overload and anaemias in which iron is present but sequestered rather than absent (Hepcidin and Iron in Health and Disease).

Inflammation, neurology and other signals

Because inflammatory signalling raises hepcidin, the peptide has been examined outside classical haematology. A 2024 paper proposed and discussed a possible role for hepcidin in intestinal inflammation (A possible role of hepcidin in intestinal inflammation). In neurology, the study of serum hepcidin in multiple sclerosis measured circulating hepcidin levels in that patient population to test whether the peptide tracked with the disease (Serum hepcidin levels in multiple sclerosis). Separate work reported hepcidin as a potential regulator of renin activity, extending interest to blood-pressure physiology (Hepcidin is potential regulator for renin activity), while a 2022 analysis described an overlooked connection between hepcidin and cadmium, a metal that shares handling pathways with iron (An Overlooked Hepcidin-Cadmium Connection).

Antimicrobial origins

Hepcidin was first noted as an antimicrobial peptide, and comparative research has continued that line: researchers identified antibacterial activity in hepcidin derived from Antarctic notothenioid fish, testing the peptide against bacterial targets (Identification of Antibacterial Activity of Hepcidin From Antarctic Notothenioid Fish). Evolutionary sequence analysis across vertebrates helps explain why fish and mammalian hepcidins differ in copy number and function (Hepcidin cDNA evolution in vertebrates).

Hepcidin as a research and therapeutic target

Because the hepcidin–ferroportin axis is a single control point, it has attracted drug-discovery attention in two opposite directions: agonists or mimetics to lower plasma iron, and antagonists to raise it. A dedicated review catalogued these approaches, describing hepcidin agonists, mini-hepcidins and hepcidin-lowering strategies as therapeutic candidates for iron overload and iron-restricted anaemia respectively (Hepcidin Therapeutics). Peptide chemistry work has focused on making short hepcidin mimetics practical: one study designed cyclic N-methylated mini-hepcidins in pursuit of orally bioavailable analogues, reporting on how cyclisation and N-methylation were used to improve peptide drug-like properties (Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins).

Adverse Events and Safety: What Studies Report

The verified papers summarised on this page were mechanistic, comparative or review articles rather than safety trials, and none of them reported a human adverse-event profile for administered hepcidin or hepcidin analogues. The therapeutics review discussed candidate agents and the rationale for modulating the axis in either direction rather than presenting tolerability outcomes (Hepcidin Therapeutics), and review literature emphasised that both excessive and insufficient hepcidin signalling are associated with disease states, which is the central caution in this field (Hepcidin and Iron in Health and Disease). Readers encountering hepcidin on a laboratory report or in a paper should discuss interpretation with a licensed clinician.

Why the term appears in peptide reading

Hepcidin is a useful teaching example of how a 25-amino-acid peptide can act as a true hormone: it is made in one organ, travels in blood, and changes the behaviour of a specific membrane transporter (Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization). It also illustrates the main obstacle in peptide development — oral delivery — which the mini-hepcidin chemistry literature addressed directly through backbone modification (Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins). No part of this page describes use in humans outside supervised research.

References

• Hepcidin and Iron in Health and Disease (Annual Review of Medicine, 2023)
• Hepcidin Therapeutics (Pharmaceuticals, 2018)
• Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization (Science, 2004)
• An Overlooked Hepcidin-Cadmium Connection (International Journal of Molecular Sciences, 2022)
• Hepcidin in beta-thalassemia (Annals of the New York Academy of Sciences, 2010)
• A possible role of hepcidin in intestinal inflammation (Arquivos de Gastroenterologia, 2024)
• Identification of Antibacterial Activity of Hepcidin From Antarctic Notothenioid Fish (Frontiers in Microbiology, 2022)
• Hepcidin is potential regulator for renin activity (PLoS One, 2022)
• Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins (Biomedicines, 2021)
• Serum hepcidin levels in multiple sclerosis (Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2019)
• Regulators of hepcidin expression (Vitamins and Hormones, 2019)
• Hepcidin cDNA evolution in vertebrates (Vitamins and Hormones, 2019)